SF 2323: Relating to the right to try Act

What it does

This bill relates to Code chapter 144E, the right to try Act. Under current law, an “eligible patient” under the Code chapter is, in part, a person who has a terminal illness. Under the bill, an “eligible patient” also includes, in part, a person who has a life-threatening or severely debilitating illness. Under current law, the Code chapter applies to an “investigational drug, biological product, or device”, meaning a drug, biological product, or device that has successfully completed phase I of a United States food and drug administration (FDA)-approved clinical trial but has not yet been approved for general use by the FDA and that remains under investigation in an FDA-approved clinical trial.

Lobbying · 3 for, 0 against

For: Americans For Prosperity; Goldwater Institute; Heartland Impact

In plain words

1. February 14, 2024Filed in the Senate
2. February 14, 2024Approved by the Senate committee